Tego' Moving Forward with Registrational Studies in Kidney and Islet Cell Transplant

Research evidence excerpt

Tego' Moving Forward with Registrational Studies in Kidney and Islet Cell Transplant

June 22, 2026

continue to impact kidney function.

●Patients who experienced rejection while on tego’ had better kidney

function vs patients who experienced rejection while on tac’.

●Patients who were on tego’ and were switched to tac’ post

rejection had lower eGFRs at month 12 vs those who rejected

and remained on their initial therapy → the P1b shows

consistent outcomes.

●For us, the maturing data are pointing to tego’s eGFR efficacy and

benefit profile that is expected from a T cell co-stimulatory inhibitor →

this should drive a differentiated long-term kidney graft function and

survival profile for tego’ vs SoC tac’.

No new or recurring rejection events occurred after mth-6 for tego’ (out to

mth-21) unlike the tac’ arm that experienced new and recurring rejection

events → this is closing the gap between the two arms and with time, we

expect the tac’ arm to accumulate more new and recurring rejections.

●Unlike the tego’ arm that saw no rejection 6-months post-transplant,

~64% of cases for tac’ occurred past this time point, including after 12

months on therapy.

●For tac’, two of the new cases involved antibody mediated

rejection.

●KOLs believe that with time, patients in the tac’ arm should

start experiencing more antibody mediated rejection and expect

much lower rates in the tego’ arm due to its MoA.

Tego’ continues to show a differentiated safety/AE profile, with lower

rates of AEs that are known to increase risk of graft failure and negatively

impact QoL → EXTENSION AE/tolerability profile consistent with that of

the P2 BESTOW.

●KOLs emphasize that meaningful improvements in safety and

tolerability would provide significant value, as many patients struggle